Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers

References

• Azarmi, S., Roa, W.H., Löbenberg, R. (2008). Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 60:863–875.
   PubMed Web of Science ®Google Scholar
• Barbro, N.M., Peter, O., Vivian, K.J. (2000). Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cells. J Hepatol. 32:603–611.
   PubMed Web of Science ®Google Scholar
• Cavalli, R., Caputo, O., Gasco, M.R. (2000). Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci. 10:305–309.
   PubMed Web of Science ®Google Scholar
• Carolina, G.G., Nicolas, T., Madeleine, B., Amelie, B., Elias, F. (2007). Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm. 331:153–159.
   PubMedGoogle Scholar
• Chin C.T., Chun C.L. (1999). Anti-inflammatory effects of Taiwan folkmedicine ‘Teng-Khia-U’ on carrageenan-and adjuvant-induced paw edema in rats. J Ethnopharmacol. 64:85–89.
   PubMed Web of Science ®Google Scholar
• China Pharmacopeial Convention. (2005). Chinese Pharmacopoeia. Section 2:184–185.
   Google Scholar
• Dik, W.A., McAnulty, R.J., Versnel, M.A., Naber, B.A., Zimmermann, LJ., Laurent, G.J., and Mutsaers, S.E. (2003). Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats. Thorax. 58:765–71.
   PubMed Web of Science ®Google Scholar
• Douglas, T., Young, M.J., Suci, P. (2010). Novel nanoparticles for biofilm targeting. United States Patent USP0021391.
   Google Scholar
• Fundaro, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., and Gasco, M. R., Non-stealth,and stealth solid lipid nanoparticles (SLN). (2000). carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharm Res. 42:337–343.
   Web of Science ®Google Scholar
• Gert, S., Sheila, 0.B., Toos, D., and Danilo, D.L. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev.17:31–48.
   Web of Science ®Google Scholar
• Ghamdi MSA. (2001). The anti-inflammatory analgesicand antipyretic activityof Nigella Sativa.. J Ethnopharmacol.76:45–48.
   PubMed Web of Science ®Google Scholar
• Grassi, M., Voinovich, D., Franceschinis, E., Perissutti, B., Filipovic-Grcic, J. (2003). Theoretical and experimental study on theophylline release from stearic acid cylindrical delivery systems. J Control Release 92:275–289.
   PubMed Web of Science ®Google Scholar
• Groeneveld, AB. (2002). Vascular pharmacology of acute lung injury and acute respiratory distress syndrome. Vasc. Pharmacol. 39:247–256.
   Web of Science ®Google Scholar
• Hoogwerf B., Danese R.D. (1999). Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am. 25:489–505.
   PubMed Web of Science ®Google Scholar
• Lange M., Malyusz M. (1994). Improved determination of small amounts of free hydroxyproline in biological fluids. Clin Chem. 409:1735–1738.
   Google Scholar
• Lu W., He L.C., Wang C.H., Li Y.H., Zhang S.Q. (2008). The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice. Int J Biol Macromol. 43:320–324.
   PubMed Web of Science ®Google Scholar
• Li, H.P., Li, X., He, G.J., Yi, X.H., Kaplan, A.P. (2004). The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycininduced pulmonary fibrosis in rats. Respirology. 9:25–32.
   PubMed Web of Science ®Google Scholar
• Löbenberg, R., Araujo, L., Von Briesen, H., Rodgers, E., Kreuter, J. (1998). Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release. 50:21–30.
   PubMed Web of Science ®Google Scholar
• Manjunath, K., Venkateswarlu, V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 107:215–228.
   PubMed Web of Science ®Google Scholar
• Mehnert, W., Ma¨der, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 47:165–196.
   PubMed Web of Science ®Google Scholar
• Mei, Z.N., Li, X. K., Wu, Q. R., Hu, S., Yang, X. L. (2005). The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharmacological Research. 51: 345–351.
   PubMed Web of Science ®Google Scholar
• Moghimi, S.M. (1995). Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block copolymers. Adv Drug Deliv Rev.16:183–193.
   Web of Science ®Google Scholar
• Müller, R.H., Maaseen, S., Schwarz, C., Mehnert, W. (1997). Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release. 47:261–269.
   Web of Science ®Google Scholar
• Müller, R.H., Radtke, M., Wissing, S.A. (2002). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 242:121–128.
   PubMed Web of Science ®Google Scholar
• Santhi, K., Dhanaraj, S.A., Koshy, M., Ponnusankar, S., Suresh, B. (2000). Study ofbiodistribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev Ind Pharm. 26:1293–1296.
   PubMed Web of Science ®Google Scholar
• Scholer, N, Hahn, H, Müller, R.H, Liesenfeld, O. (2002). Effect of lipid matrix and size of solid lipid nanoparticles (SNLC) on the viability and cytokine production of macrophages. Int J Pharm. 231:167–176.
   PubMed Web of Science ®Google Scholar
• Scholer, N, Olbrich, C, Tabatt, K, Müller, R.H, Hahn, H, Liesenfeld O. (2001). Surfactant, but not the size of solid lipid nanoparticles (SNLC) influences viability and cytokine production of macrophages. Int J Pharm. 221:57–67.
   PubMed Web of Science ®Google Scholar
• Souto, E.B., Wissing, S.A., Barbosa, C.M., Müller, R.H. (2004). Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J. Pharm Biopharm. 58:83–90.
   PubMed Web of Science ®Google Scholar
• Speiser, P. (1990). Lipidnanopellets als Tragersystem fur Arzneimittel zur peroralen Anwendung. European Patent EP0167825.
   Google Scholar
• Sun, J.Y., Zhou, Z.F., Liu, F., Chen, G.S. (2007). Pharmacokinetics and tissue distribution of oxymatrine-SLN. Chin Pharm J. 42:1091–1095.
   Google Scholar
• Sung, H.K., Dal, W.C., Choon, W.K., Sang, G.K. (2005). Lack of therapeutic improvement of liver fibrosis in rats by dexamethasone in spite of ascites amelioration. Chem Biol Interact. 152:37–47.
   PubMed Web of Science ®Google Scholar
• Vighi, E., Ruozi, B., Montanari, M., Battini, R., Leo, E. (2007). Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind pEGFP-plasmid. Eur J Pharm Biopharm. 67:320–328.
   PubMed Web of Science ®Google Scholar
• Wang, M.T., Jin, Y., Yang, Y.X., Zhao, C.Y., Yang, H.Y., Xu, X.F., Qin, X., W, Z.D., Zhang, Z.R., Jian, Y.L., Huang. Y. (2010). In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system. Int J Nanomedi. 5:487–497.
   PubMed Web of Science ®Google Scholar
• Wang, J.X., Sun, X., Zhang, Z.R. (2002). Enhanced brain targeting by synthesis of 3, 5-dioctanoyl-5-fluoro-2-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm. 54:285–290.
   PubMed Web of Science ®Google Scholar
• Yang, S.C., Lu, L.F., Cai, Y., Zhu, J.B., Liang, B.W., Yang, C.Z. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 59:299–307.
   PubMed Web of Science ®Google Scholar
• Ye, J.S., Wang, Q., Zhou, X.F., Zhang, N. (2008). Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm. 352:273–279.
   PubMed Web of Science ®Google Scholar
• Yu, B.T., Zhang, Z.R., Zeng, R.J. (2000). Study on the liver targeted 5-fluorouracil solid lipid nanoparticles. Yaoxue Xuebao. 35:704–705.
   Google Scholar
• Zara, G.P., Cavalli, R., Fundarò, A., Bargoni, A., Caputo, O., Gasco, M.R. (1999). Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res. 40:281–286.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Dirk, W., Grijpma, J.F. (2006). Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone. J Control Release. 111:263–270.
   PubMed Web of Science ®Google Scholar
• Zhao, C.Y., Liu, Y., Fan, T.T., Zhou, D., Yang, Y., Jin, Y., Zhang, Z.R., Huang, Y. (2011). A novel strategy for encapsulating poorly soluble drug into nanostructured lipid carriers for intravenous administration. Pharm Dev Technol. 1–14, Early Online.
   PubMedGoogle Scholar